Drug intelligence / Profile preview

SI (JW Theriac Pharmaceutical)

Development stage: Preclinical
Lead developer: JW Theriac Pharmaceutical
Modality: Small Molecules

Overview

**SI** is an undisclosed preclinical small-molecule **STAT6 inhibitor** being developed by **JW Theriac Pharmaceuticals** for **immunological diseases**. Publicly available pipeline information identifies the program only by the code name SI and lists its intended target as signal transducer and activator of transcription 6, suggesting a targeted immunology program aimed at modulating STAT6-driven inflammatory signaling.

Other names: SI

Targets

STAT6 (Signal Transducer and Activator of Transcription 6)

Beyond the preview

Go deeper on SI (JW Theriac Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SI (JW Theriac Pharmaceutical).

Explore the full profile